Evoke Pharma (EVOK) Posts Smaller-than-Expected Q4 Loss
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Needham Starts NeoVolta (NEOV) at Buy
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- KKR launches Helix with over $10 billion to build AI infrastructure
Evoke Pharma Reports Fourth Quarter and Full Year 2017 Financial Results and Recent Highlights
March 7, 2018 4:05 PM ESTSuccessfully completed pivotal pharmacokinetic trial and finalized the proposed to-be-marketed Gimoti doseAnnounced discovery of sex-based pharmacokinetic differences for GimotiMet with FDA regarding NDA women-only filing strategy and post-marketing plans505(b)(2) NDA submission planned for second quarter of 2018Â Â Â Â Â Â Â
SOLANA BEACH, Calif., March 07, 2018 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced its financial results for the fourth quarter and full year ended... More
